Abbott's Humira Defense Hinges On Appeal - And A Countersuit in Massachusetts
This article was originally published in The Pink Sheet Daily
Executive Summary
J&J awarded $1.67 billion by Texas jury in patent infringement case; Humira is the subject of three other suits.
You may also be interested in...
Lilly Laid Groundwork For Abbott's Defeat Of J&J's Patent Verdict On Humira
Abbott Laboratories had reason to thank Eli Lilly & Co. when the U.S. Court of Appeals for the Federal Circuit overturned a record $1.67-billion jury verdict that Abbott's Humira infringed a Johnson & Johnson patent.
Lilly Laid Groundwork For Abbott's Defeat Of J&J's Patent Verdict On Humira
Abbott Laboratories had reason to thank Eli Lilly & Co. when the U.S. Court of Appeals for the Federal Circuit overturned a record $1.67-billion jury verdict that Abbott's Humira infringed a Johnson & Johnson patent.
Follow-On Biologics “Integrally Related” To Patent Reform Bill, Sen. Hatch Says
Remarks suggest the potential for an alternate vehicle for addressing brand firms’ concerns about patent certainty, even as work on overall health care reform intensifies.